Back to News
Market Impact: 0.2
BioVie To Present Phase 2 ADDRESS-LC Topline Data On Bezisterim's Potential In Long COVID; Today
Source: Nasdaq
Healthcare & Biotech
BioVie Inc. will host a conference call and webcast on September 15, 2026, at 8:30 a.m. ET to discuss topline results from its Phase 2 ADDRESS-LC trial of Bezisterim. The announcement provides no clinical efficacy, safety, or financial results ahead of the event.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BIVI0.15
More News
- BioVie reports phase 2 long COVID trial results
- Wells Fargo sees improvement in a key metric — plus, Lilly gets praise beyond GLP-1s
- Inside South Korea’s university programs offering a direct route to Samsung and SK Hynix
- A sharp stock market decline could lie around the corner, Wells Fargo warns
- Why is Vera Therapeutics stock reversing its premarket gains?
- H.C. Wainwright raises Scholar Rock stock price target on FDA approval
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?